Original Contribution
Stromal Expression of CD10 in invasive Ductal Carcinoma and its relationship
with ER, PR and HER2-neu Status
1.*Dr. Farah Imrana, MD (Histopathology), Assistant Professor, BIHS General Hospital. 125/1Darus
Salam, Mirpur, Dhaka.. farahdr02@gmail.com
2. Dr. Md. Shahriar Mamun, Assistant Professor (cc), Department of Pathology, Satkhira Medical College.
3. Dr. SM Moshadeq Hossain, Assistant Professor, Pathology, Rajshahi Medical College.
4. Dr. Alimul Hassan, Clinical Pathologist, Rangpur Medical College Hospital.
*For correspondence
Abstract
Background: Ductal carcinoma is a common type of breast cancer that starts in cells of milk ducts
and can enhance the risk of developing invasive breast cancer in the long run. The study aimed to
evaluate the stromal expression of CD10 in Invasive Ductal Carcinoma and its relationship with
ER, PR, and HER-2 status.
Methods: This cross-sectional study was carried out in the Department of Pathology, Rajshahi
Medical College, Rajshahi, from July 2017 to December 2018, to evaluate the expression of
stromal CD10 in invasive breast carcinoma and to correlate with ER, PR, HER 2/neu status in
mastectomy or lumpectomy specimen. A total of 50 cases of mastectomy or lumpectomy
specimens will be taken that were received in the Department. Samples were selected by the
purposive sampling technique.
Results: In the present study, out of total 50 cases, most of the study subjects that is 17 (34%)
belonged to the age group of 51-60 years. Estrogen receptor were positive in 29(58.0%) cases,
progesterone receptor was positive in 16(32.0%) cases. The association between estrogen receptor
status with stromal CD10, all the 16 (100.0%) CD 10 strong positive cases were negative for
estrogen receptor. In CD10 negative group, almost all 28 (96.6%) cases were positive for estrogen
receptor. The difference was statistically significant (p<0.05).
Conclusion: Substantial knowledge regarding stromal contribution to cancer progression could
help researchers to identify particular signals which could lead to the revelation of new therapeutic
targets in the future.
[Journal of Histopathology and Cytopathology, 2023 Jan; 7 (1):36-44]
Keywords: Ductal carcinoma, CD10, Estrogen receptor, Progesterone receptor, Her-2, Invasive
Full Article